Invitae, which offers consumers a suite of genetic tests as a single service, announced terms for its IPO on Monday. The San Francisco, CA-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Invitae would command a fully diluted market value of $436 million.
Invitae, which was founded in 2010 and booked $1 million in sales for the 12 months ended September 30, 2014, plans to list on the NYSE under the symbol NVTA. J.P. Morgan is the sole bookrunner on the deal. It is expected to price during the week of February 9, 2015.
